MISCELLANEOUS

Year : 2018  |  Volume : 8  |  Issue : 1  |  Page : 35-41

Information for authors - Medical Gas Research

Correspondence Address:

Source of Support: None, Conflict of Interest: None

Check

PMID: 29770196

• Emerging Sources Citation Index (ESCI)
• PubMed
• PubMed Central (PMC)
• Scimago Journal Ranking (SJR)
• DOAJ
• Baidu Scholar
• China National Knowledge Infrastructure (CNKI)
• Index of Copurnicus (IC)
• EBSCO Publishing’s Electronic Databases
• Exlibris – Primo Central
• Google Scholar
• Hinari
• Infotrieve
• National Science Library
• ProQuest
• TdNet
• SCOPUS

• The study presents the results of primary scientific research.
• Experiments, statistics, and other analyses are performed to a high technical standard and are described in sufficient detail.
• Results reported have not been published elsewhere.
• Conclusions are presented in an appropriate fashion and are supported by the data.
• The research meets all applicable standards for the ethics of experimentation and research integrity.
• The article adheres to appropriate reporting guidelines and community standards for data availability.
• The article is presented in an intelligible fashion and is written in Standard English.

• Response to reviewers form: Address the specific points made by each reviewer.
• Revised manuscript (traced copy): Include a traced copy of your manuscript file showing the changes you have made on the original submission.
• Revised manuscript (clean copy): Upload a clean copy of your revised manuscript that does not show your changes.

• The manuscript is original, has not been submitted to or is not under consideration by another publication and has not been previously published in any language or any form, including electronic.
• All authors approve the final version of the manuscript and of its submission to MGR.
• Recommending 3–5 scientists as peer reviewers for your manuscript, including their contact information. The suggested reviewers should be in the same field of your study, and from different institutions and have not copublished articles previously.
• Once submitted to MGR, the manuscript should not be submitted to other journals within 1 month, whether it is undergoing or awaiting the paper review process.

• Research Articles: reports of data from original research.
• Review: comprehensive, authoritative, descriptions of any subject within the journal’s scope. Reviews can cover any topical themes such as basic science and clinical reviews, ethics, pro/con debates, equipment reviews and thematic series to highlight specific topics in the field.
• Short Communication: brief reports of data from original research, usually about 1,500 words.
• Case Report: reports of clinical cases that can be educational, describe a diagnostic or therapeutic dilemma, suggest an association, or present an important adverse reaction.
• Commentary: short, focused and opinionated articles on any subject within the journal’s scope. These articles focus on specific issues and are about 800 words.
• Letter to the Editor: these can take three forms: a substantial re-analysis of a previously published article, or a substantial response to such a re-analysis from the authors of theoriginal publication, or an article that may not cover “standard research” but that may be relevant toreaders.

• Medical researchers should abide by international guidelines for the care and use of laboratory animals, the Weatherall report on the use of non-human primates in research (2006), and The National Centre for the Replacement, Refinement and Reduction of Animals in Re-search (NC3Rs).
• The authors’ institutional animal care and use committee that approved the animal experiments and the associated permit number(s) should be stated in research papers.
• The methods section of MGR papers must include ethics statements, e.g. “The protocol was approved by the Animal Ethics Committee of XXX University (approval number: XXX). All surgery was performed under sodium pentobarbital anesthesia, and all efforts were made to minimize animal pain, distress, and death.” Guidelines for euthanasia methods approved by MGR for use in animal experiments is shown in [Table 1].

  Table 1: Examples of Data Sharing Statements that Fulfill these ICMJE Requirements* Click here to view

• Data and methods published in MGR should be shared for replication of the results by others. Original experimental data or DOI numbers registered in data repository should be provided upon submission to facilitate understanding of peer reviewers and transparency to other audiences.
• Original data from studies involving genes, proteins, mutants and diseases should be registered on recognized public databases e.g. figshare or re3data, and the registered identifier should be provided upon submission.
• A small amount of data or certain special data may be submitted as supplementary data online.
• For data mining from other open-access databases, the source must be indicated.
• Studies involving animal experiments should be reported according to ARRIVE guidelines (https://www.nc3rs.org.uk/arrive-guidelines).

• All studies performed involving human should be registered in clinical trials registry platform, such as clinicaltrials.gov, prior to participant recruitment. The registry platform and register identifier should be provided upon submission and included in the abstract of the manuscript.
• The ethics committee and the approval number(s) should be stated in papers. Prospective clinical studies with no registration will not be accepted by MGR. In addition, informed consent of study and protocol verion should be indicated.
• Clinical manuscripts should be written according to the reporting guidelines at www.equator-network.org. Additionally, checklists and a flow chart should be provided upon submission.

• Each MGR paper will be checked twice, using Crosscheck to verify originality after submission and prior to publication. The check report will be sent to the authors.
• The similarity of any MGR paper should not be over 5% against one single published paper, nor over 20% against all published papers.
• Similarity between new submitted manuscript and the published by the same research team or author should be not over 50%.
• No retracted articles should be cited.
• For dishonorable events including redundant (duplicate) publication, suspected plagiarism, and undisclosed conflicts of interest, MGR will abide by the regulations suggested by COPE guidelines (http://publicationethics.org/resources).

• MGR publishes corrections, retractions, and expressions of concern as appropriate, and as quickly as possible. We follow the ICMJE and COPE guidelines where applicable.
• Correction: A notice of correction will be issued by MGR to correct substantial errors that appear in published articles when these errors significantly affect the content or understanding of the work (e.g., error in data presentation or analysis) or when the error affects the publication’s metadata (e.g., misspelling of an author’s name). In these cases, MGR will publish a correction that will be linked to the original article. In very rare cases, we may choose to correct the article itself and repost it online. If that course is taken, a correction notice will also be created to document the changes to the original article.
• Author-Initiated Retractions: MGR will retract an article at the authors’ request at any time unless it is under review for a possible violation of Responsible Conduct Regarding Scientific Communications. At the authors’ option, the retraction notice may simply state that the article has been retracted at the authors’ request. Alternatively, the authors may provide a brief explanation of the error(s) prompting the retraction. However, statements of retraction may not assign blame to specific authors or laboratories.
• Retractions: The editors reserve the right to retract an article at any time after publication without the consent of the authors if an investigation by an appropriate authority reveals a violation of MGR’s Ethics Policy.
• To request a correction/retraction, please contact the editorial office directly at [email protected]

• The publisher retains all rights concerning assembling, printing, reproducing, translating, disseminating, exhibiting, publishing, retrieving and indexing part or all of the contents of the article.
• After signing transfer of copyright with the journal, the authors retain the rights.
• In not-for-profit circumstances, the use, dissemination and reproduction of part or all of the contents of the article is permitted when cited appropriately.

• Word limit: 4,000-6,000 words, 8-10 published pages.
• Title: 90 characters (20 words) maximum.
• Abstract: 250 words maximum, unstructured abstract.
• Graphical abstract:
• Introduction: 1,000 words maximum.
• Materials/Subjects and Methods:
• Results:
• Discussion: 1,000 words maximum.
• Acknowledgments:
• Declaration of patient consent (only for clinical studies):
• Author contributions:
• Conflicts of interest:
• Financial support:
• References: 50 minimum; 30% of cited references should have been published within the preceding 3 years; use the reference style of American Medical Association (AMA) Citaxion Style.

• Word limit: 6,000 words minimum including the abstract, but excluding references, tables and figures. 8-10 published pages.
• Structure:
• Title: 90 characters (20 words) maximum.
• Abstract: 250 words maximum, unstructured abstract.
• Introduction:
• Body text:
• Acknowledgments:
• Author contributions:
• Conflicts of interest:
• Financial support:
• References: use the reference style of AMA Citaxion Style.

• A short communication sent to MGR publisher about issues of concern from its readers.
• Word limit: 500-1,000 words maximum, excluding references. No abstract, tables and figures, 1 published page.
• Title: 90 characters (20 words) maximum.
• Body text:
• References: 5 maximum; use the reference style of AMA Citaxion Style.

• A case report sent to MGR publisher about issues of concern from its readers.
• Word limit: 500-1,000 words maximum, excluding references. No abstract, tables and figures, 1 published page.
• Title: 90 characters (20 words) maximum.
• Body text:
• References: 5 maximum; use the reference style of AMA Citaxion Style.

• A commentary report sent to MGR publisher about issues of concern from its readers.
• Word limit: 500-1,000 words maximum, excluding references. No abstract, tables and figures, 1 published page.
• Title: 90 characters (20 words) maximum.
• Body text:
• References: 5 maximum; use the reference style of AMA Citaxion Style.

• A letter sent to MGR publisher about issues of concern from its readers.
• Word limit: 500-1,000 words maximum, excluding references. No abstract, tables and figures, 1 published page.
• Title: 90 characters (20 words) maximum.
• Body text:
• References: 5 maximum; use the reference style of AMA Citaxion Style.

• Should be brief (less than 20 words, 90 characters maximum), novel and informative.
• Should attract the reader’s attention.

• Should accurately reflect the main points of the paper.
• 40 characters maximum.
• Should facilitate retrieval.

• Full name of the first author and his/her afiliations (including department, institution, city with postal code and state/country, telephone number and fax number).
• For corresponding author, please list name, highest academic degree earned, professional titles, detailed correspondence address, telephone number, fax number and e-mail address.
• Indicate author contributions, grants, acknowledgments and conflicts of interest.
• Declaration of patient consent: The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

• Image size: a minimum of 531 × 1,328 pixels (height × width); image width within the full-text width (18 cm); resolution ≥ 300 dpi.
• File type: JPG, TIFF, PDF, or MS Office files are preferred.
• Font: Arial or Times New Roman.

Introduction

• Present the nature and scope of the problem being investigated.
• Review briefly the pertinent literature.
• Provide an innovative context for the study in relation to previous work.
• State the hypothesis and the objectives of the paper.
• 1,000 words maximum.

Materials/Subjects and Methods

Results

• Objectively and accurately describe the major findings from each experiment, and try to minimize shortcomings that will draw attention from the peer reviewers.
• Describe the findings, from major to minor. -Use illustrations (e.g., graphs, drawing or photographs) where appropriate. Graphs and drawings should be self-explanatory.

Discussion

• Word limit: 1,000 words maximum.
• Discuss the major novel findings of the study and describe the different characteristics from other studies.
• Explain and extrapolate the major findings of the study; state whether the findings sup-port some viewpoint or not; purpose the new problems or concerns.
• Discuss the significance of the major findings and how they advance the knowledge in the field of neural regeneration.
• Provide a conclusion that clearly indicates how the results met the objectives. Do not offer a conclusion that is not supported by sufficient data.
• Disclose the limitations and bias to embody the authenticity of the contents.
• Make suggestions for the future direction of research that builds on your findings.
• Indicate the theoretical significance and practical application value of the present results and make a strong conclusion.

References

• All illustrations (e.g., graphs, drawings and photographs) are considered to be figures. Each figure should be provided with a fully descriptive title and legend. The area(s) of interest must be clearly indicated with arrows or other symbols. Figure legends must be self-explanatory, which should provide sufficient detail to be intelligible without reference to the main text. All micrographs should contain a magnification scale bar. Please position the scale bar in the lower right corner of one micrograph or of the last panel (for multiple panels). The length of the scale bar should be indicated on the images or in the figure legend. The images contained in a figure are arranged in the sequence from top left to bottom right. Tags (A, B, C…) are posi-tioned in the upper left corner of each image. All abbreviations and labels appearing on the image should be explained in figure legends. If figures have been reproduced from another source, written permission for reproducing the material must be attached to the covering letter. Figures should be cited consecutively in the text and number them in that order. Each figure should be placed on a separate sheet after the reference list, including the figure title and legend. The figure title should be not lettered onto the figure itself. All measurements in the figure are in SI (metric) units. Acomma should be used to separate thousands. Labels including “*, **, ***, #, ##, ### (in that order)” are used to identify the statistical difference between datasets in the histograms or line drawings.
• Color figure: resolution: > 300 dpi; file format PNG, EPS, TIFF, or PDF; CMYK mode should be used rather than RGB; use of high contrasting colors for color discrimination.
• Line figures: resolution > 1,200 dpi; line width between 0.5 and 1 point; file format EPS, PDF or TIFF.
• Grayscale figures: resolution > 600 dpi; file format EPS, TIFF or PDF. Figures should remain clear at 300-fold magnification. Figures should be sized to fit within the column (9 cm) or the full-text width (18 cm). All labels on the figure should be typed in Arial or Times New Roman font and be clearly legible.

• ARRIVE guideline (Animal Research: Reporting of In Vivo Experiments): The ARRIVE guidelines are recommended for in vivo experiments in animals. See https://www.nc3rs.org.uk/arrive-guidelines for more information.
• CONSORT statement (Consolidated Standards of Reporting Trials): The CONSORT statement is recommended for reporting randomized controlled trials. The authors are encouraged to complete 25-item checklist in their cover letter. In addition, the registration identification number and protocol version of the randomized controlled trial is listed at the end of the Abstract. See http://www.consort-statement.org/ for more information.
• STARD statement (STAndards for the Reporting of Diagnostic accuracy studies): This checklist is recommended for reporting diagnostic accuracy studies. See http://www.stard-statement.org/ for more information.
• STREGA statement (STrengthening the REporting of Genetic Associations): These guidelines are recommended for the reporting of genetic association studies. See http://www.strega-statement.org/ for more information.
• STROBE statement (STrengthening the Reporting of OBservational studies in Epidemiology): These guidelines are recommended for the reporting of observational studies in epidemiology). See http://www.strobe-statement.org/ for more information.
• TREND statement (Transparent Reporting of Evaluations with Nonrandomized Designs): These guidelines are recommended for the reporting of non-randomized evaluations of behavioral and public health interventions. See http://www.cdc.gov/trendstatement/ for more information.
• MOOSE checklist (a Reporting Checklist for Authors, Editors, and Reviewers of Meta-analyses of Observational Studies): This checklist is recommended for meta-analyses of observational studies. See https://www.editorial-manager.com/jognn/account/MOOSE.pdf for more information.
• PRISMA statement (Preferred Reporting Items for Systematic Reviews and Meta-Analyses): The PRISMA Statement is recommended for the reporting of systematic evaluation and meta-analysis articles. See http://www.prisma-statement.org/ for more information.
• Equator Network (standards for Enhancing the QUAlity and Transparency Of health Research): This organization works to improve the reliability and value of reports on medical research studies by promoting transparent and accurate reporting of research studies. See http://www.equator-network.org for more information.